BI-2852

pan-KRAS inhibitor

Also Known As:

(3S)-5-hydroxy-3-(2-(((1-((1-methylimidazol-4-yl)methyl)indol-6-yl)methylamino)methyl)-1H-indol-3-yl)-2,3-dihydroisoindol-1-one

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Neoplasms (Cancer) 01/01/2019 - "Researchers have developed a KRAS inhibitor, BI-2852, that inhibits ERK phosphorylation and reduces proliferation of KRAS-mutant cancer cells. "